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Summary
Background: Depressive patients often have altered cortisol secretion, but few studies have
investigated genetic variants in relation to both cortisol secretion and depression. To identify
genes related to both these conditions, we: (1) tested the association of single nucleotide
polymorphisms (SNPs) in hypothalamic—pituitary—adrenal-axis (HPA-axis) candidate genes with
a summary measure of total cortisol secretion during the day (cortisolAUC), (2) performed a
genome wide association study (GWAS) of cortisolAUC, and (3) tested the association of identified
cortisol-related SNPs with depressive symptoms.
Methods: We analyzed data on candidate SNPs for the HPA-axis, genome-wide scans, cortisol
secretion (n = 1711) and depressive symptoms (the Centre for Epidemiology Studies Depression
Scale, CES-D) (n = 2928) in elderly persons of the Rotterdam Study. We used data from the
Whitehall II study (n = 2836) to replicate the GWAS findings.
Results: Of the 1456 SNPs in 33 candidate genes, minor alleles of 4 SNPs (rs9470080, rs9394309,
rs7748266 and rs1360780) in the FKBP5 gene were associated with a decreased cortisolAUC
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( p < 1  10(4) after correction for multiple testing using permutations). These SNPs were also
associated with an increased risk of depressive symptoms (rs9470080: OR 1.19 (95%CI 1.0; 1.4)). The
GWAS for cortisol yielded 2 SNPs with p-values of 1  10(06) (rs8062512, rs2252459), but these
associations could not be replicated.
Conclusions: These results suggest that variation in the FKBP5 gene is associated with both
cortisolAUC and the likelihood of depressive symptoms.
# 2011 Elsevier Ltd. 
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The diurnal secretion of cortisol is characterized by high
levels in the morning followed by a decline in cortisol levels
toward the evening, and reflects the total cortisol exposure
during day time. After its release from the adrenal glands,
cortisol exerts diverse actions including on the immune
system, glucose metabolism and the central nervous system.
The effect of cortisol on target organs is mediated by two
types of receptor: the mineralocorticoid receptor (MR
(NR3C12)) and the glucocorticoid receptor (GR (NR3C1)).
In the brain, MR mediates the onset of the stress response,
whereas GR is involved in the termination of the stress
response. The heritability of diurnal cortisol secretion has
been estimated at 62% (Bartels et al., 2003).
Several studies have shown that depression is associated
with hyperactivity of the hypothalamic—pituitary—adrenal
(HPA) axis resulting in high cortisol levels (Holsboer, 2000;
Ehlert et al., 2001; Vreeburg et al., 2009) and abnormal
cortisol secretion in response to standard stimuli, such as
the DEX/CRH suppression test (Heuser et al., 1994). It has
been suggested that these alterations in cortisol secretion
are causally related to the development of depression and for
this reason the identification of genes related to cortisol
secretion may enhance the discovery of genes associated
with depression (Gottesman and Gould, 2003). Recent studies
provide some support for this hypothesis. For example, single
nucleotide polymorphisms (SNPs) in the MR gene have been
associated with morning cortisol levels (van Leeuwen et al.,
2009) and, in elderly subjects, with the prevalence of depres-
sive symptoms (Kuningas et al., 2007). SNPs within the GR
gene have been associated with hypersensitivity to cortisol,
the occurrence of depression, and the response to antide-
pressant treatment (Spijker and van Rossum, 2009). The
FK506 binding protein 5 (FKBP5), which acts as co-chaperone
of GR, is associated with the sensitivity of GR to cortisol and
SNPs within the FKBP5 gene have been shown to be associated
with depression (Lekman et al., 2008; Zobel et al., 2010),
treatment response and recurrence of depressive episodes
(Binder et al., 2004). However, most of these studies exam-
ined cortisol secretion under stressful circumstances without
an assessment of basal cortisol secretion. In the current
study, we sought to find genes related to cortisol secretion
and ultimately to depressive symptoms. We measured saliva
cortisol concentrations during the day, which approximate
free plasma cortisol (Kirschbaum and Hellhammer, 1994;
Gozansky et al., 2005). To prevent multiple testing and to
increase precision, we applied a commonly used summary
measure of total cortisol secretion during the day expressed
as the area under the curve (cortisolAUC) (Pruessner et al.,
2003). First, we performed a candidate gene study of corti-
solAUC. Candidate gene studies rely on biological knowledgeand are able to examine the postulated association with more
power as multiple testing is not so stringent as less tests are
peformed due to prior selection. However, this approach does
not identify new genes. Therefore, we also performed a
hypothesis free GWAS to try to discover genes not previously
associated with HPA-axis functioning. Third, we examined
the effect of the SNPs associated with cortisolAUC in the
candidate gene study and/or GWAS on the risk of depressive
symptoms.
2. Methods and materials
2.1. Setting and study population
This study is embedded in the Rotterdam Study, an ongoing
population-based cohort on risk factors for chronic diseases
in the elderly. Detailed information on design, objectives and
methods has been presented elsewhere (Hofman et al.,
2009). The Medical Ethics Committee of the Erasmus Medical
Center approved the Rotterdam study and written informed
consent was obtained from all participants. Of the 3550
participants of the fourth study survey (2002—2004), genetic
and cortisol data were available in 1711 persons. In 2928
participants, genetic data and information about depressive
symptoms were available.
2.2. Candidate genes and genome-wide data
Based on the literature, we selected candidate genes known
to be involved in central regulation of the HPA-axis, cortisol
biosynthesis in the adrenal, or the clearance of cortisol from
the circulation (Table 2). To select SNPs within the candidate
gene regions, we included 100 kb at 50and 30 of the genes to
e.g. include regulatory regions. We then extracted these
SNPs from the GWAS genotyping, using PLI NK v1.02 (Purcell
et al., 2007).
The genome-wide genotyping was done with the Illumina
550K array (Illumina, San Diego, CA, USA) in self-reported
Caucasian individuals (sample call rate 97.5%) (Richards
et al., 2008). We excluded individuals for excess autosomal
heterozygosity, mismatch between genotypic and phenotypic
gender, and outliers identified by the identity-by-state (IBS)
clustering analysis. SNPs were excluded when the minor allele
frequency (MAF) was 1% or less, the Hardy—Weinberg equili-
brium (HWE) p-value was smaller than 1  10(5), or the SNP
call rate was 90% or less. This resulted in 530,683 SNPs.
2.3. Cortisol collection
Participants were asked to collect saliva samples at home
using Salivette sampling devices (Sarstedt, Rommelsdorf,
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participants received detailed oral and written instructions
concerning the saliva sampling, and were asked to collect
four saliva samples during one single weekday: at awakening,
30 min later, at 5 pm and at bedtime. Samples were stored in
the freezer at 80 8C and later sent to the laboratory of
Biopsychology, TU Dresden, Germany. Salivary cortisol con-
centrations were measured using a commercial immunoassay
with chemiluminescence detection (CLIA; IBL Hamburg, Ger-
many). Intra- and interassay coefficients of variation were
below 6% and 9%, respectively. In line with a previous study
(Dekker et al., 2008), cortisol values above the 98th percen-
tile in the original cortisol dataset were excluded.
2.4. Depressive symptoms
Depressive symptoms were assessed using the Centre for
Epidemiology Studies Depression Scale (CES-D) which is a
validated and reliable self-report measure (Radloff, 1977).
The CES-D consists of 20 items with total scores ranging from
0 to 60. We used a cut-off of 16 or higher to dichotomize
depressive symptoms. This cut-off is indicative of clinically
relevant symptoms and a sensitive threshold for depressive
disorder (Beekman et al., 1997).
2.5. Other covariates
Information about gender, age, educational level, smoking
habits was assessed by interview, coronary heart disease
(fatal or nonfatal myocardial infaction, a percutaneous trans-
luminal coronary angioplasty, a coronary artery bypass graft,
other forms of acute or chronic ischemic heart disease,
sudden cardiac death, and death due to ventricular fibrilla-
tion and congestive heart failure), diabetes mellitus type II
was assessed by fasting glucose levels and the use of anti-
diabetic medication, use of hypnotics, antidepressants and
antipsychotics was assessed by cabinet check.
2.6. GWAS replication study
The Whitehall II Cohort recruited participants between 1985
and 1988 (phase 1) from 20 London-based civil service
departments. Data reported here are from the phase 7
(2002—2004) data collection when large-scale genotyping
was undertaken for the first time. Saliva samples were
returned by 90.1% (n = 4609) of the participants who
attended the screening clinic (Badrick et al., 2007). Details
of the clinical assessment and cohort profile have been
reported elsewhere (Marmot and Brunner, 2005).
The protocol of saliva collection has been described pre-
viously (Badrick et al., 2007). Briefly, participants were
requested to provide six saliva samples over the course of
a normal weekday at awakening, waking +30 min, waking
+2.5 h, waking +8 h, waking +12 h and bedtime. Salivary
cortisol levels were measured using a commercial immunoas-
say with chemiluminescence detection (CLIA; IBL Hamburg,
Germany).
SNPs were genotyped at kbioscience (http://www.kbios-
cience.co.uk) using KASPar chemistry, which is a competitive
allele-specific PCR SNP genotyping system using FRET
quencher cassette oligos. Blind duplicates, plate-identifyingblank wells and Hardy—Weinberg equilibrium tests were used
as quality control tests. Cortisol data and genotype data were
available in 2836 white participants of the Whitehall II Study.
2.7. Statistical analyses
First, we determined the total diurnal cortisol secretion with
respect to the ground expressed by the area under the curve
(cortisolAUC). This is given by the cortisol measurements in
nmol/L on the y-axis and the time between the cortisol
measurements on the x-axis (Pruessner et al., 2003). To correct
for differences in length of total sampling interval, the corti-
solAUC was divided by time awake during the day in hours. The
unit of cortisolAUC is thus (nmol  h/L)/h = nmol/L.
Second, we performed a linear regression analysis to
examine the association of SNPs of candidate genes with
the cortisolAUC. p-values of these associations were corrected
for multiple testing using the Max(T) permutation procedure
(10,000 permutations). The regression analysis and the per-
mutation procedure were performed using PLINK v1.02 (Pur-
cell et al., 2007).
Third, we performed a genome-wide quantitative trait
analysis of diurnal cortisol secretion using PLI NK v1.02
(Purcell et al., 2007). The Hardy—Weinberg equilibrium
(HWE) p-value was set at 1  10(4), the maximum percen-
tage SNPs per person missing at 2%, and the threshold for the
minor allele frequency (MAF) at 1%. We also performed a
GWAS in females and males separately.
Fourth, to replicate our GWAS findings we selected SNPs of
the GWAS based on p-values (<1  10(5)) and LD between
SNPs. We also selected SNPs of the GWAS that were located in
candidate genes and showed a strong association ( p-value
<1  10(4)) with the cortisolAUC. We tested the association
of these selected SNPs of the GWAS with cortisol data of the
Whitehall II Study using linear regression analyses in an
additive model (SPSS Inc., Chicago, IL, USA). Next, we per-
formed a meta-analysis using the inverse Z score method
assuming fixed effects (R 2.8.1).
Fifth, we tested the association of statistically signifi-
cantly associated SNPs in the candidate gene study or the
GWAS with clinically relevant depressive symptoms in parti-
cipants of the Rotterdam Study using logistic regression
analysis in PLINK v1.02 (Purcell et al., 2007), adjusted for
age and gender. To examine if the association of SNPs and
depressive symptoms could be explained by other character-
istics, we tested if non-carriers and carriers differed with
respect to gender, age, educational level, smoking, diabetes
mellitus type II, coronary heart disease, or the use of hyp-
notics, antidepressants and antipsychotics.
3. Results
3.1. GWAS sample and replication sample
Table 1 presents the characteristics of participants of the
GWAS discovery sample and the replication sample. Partici-
pants of the GWAS discovery sample were more likely female,
and were, on average, older than participants in the replica-
tion sample. Furthermore, people in the GWAS discovery
sample were more likely to smoke, less highly educated,
and were more likely to report diabetes mellitus type II,
Table 1 Characteristics of Rotterdam Study participants and Whitehall II Study participants with cortisol data.
Rotterdam study (n = 1711)a Whitehall II study (n = 2836)a
Gender (male) 45.4% 77.7%
Age (yrs.) 74.9(5.7) b 60.9 (5.9)b
Education
University/polytechnic 12.0% 37.1%
Smoking 12.5% 7.7%
Diabetes mellitus Type II 5.4% 6.6%
Coronary heart disease 13.2% 4.5%
Hypnotics 14.1% 1.2%
Antidepressants/antipsychotics 4.5% 4.0%
Cortisol (nmol/L)
At awakening 13.17(0.01—42.97) 14.80(0.10—40.05)
30 min. after awakening 16.80(0.06—51.12) 21.82(0.01—54.52)
8 h. after awakening 3.42(0.01—19.09) 5.13(0.00—19.50)
At bedtime 1.64(0.02—13.42) 1.50(0.00—13.59)
CortisolAUC (nmol/L) 8.14(3.47)
b 6.93(2.29)b
Numbers are median (100% range) unless otherwise indicated.
a t test and Mann—Whitney test for continuous variables and Chi-square tests for dichotomous variables.
b Mean (standard deviation).
1056 F.P. Velders et al.coronary heart disease and the use of hypnotics. Also, there
were small differences in cortisol levels between the two
samples.
3.2. The candidate gene study
The list of 33 candidate genes, the number of SNPs within
these genes (1456 in total), and their position are presented
in Table 2. Initially, 96 of 1456 SNPs were associated with the
cortisolAUC with a p-value less than or equal to 0.05 (see
supplementary material (SM) Table 2), of which Table 3 shows
the top 10 SNPs located in 7 genes; the FK506 binding protein
5 (FKBP5) gene, the melanocortin 4 receptor (MC4R) gene,
the corticotrophin-releasing hormone receptor 2 (CRHR2)
gene, the arginine vasopressin (AVP) gene, the steroid-5-
alpha-reductase (SRD5A1) gene, the mineralocorticoid
receptor (NR3C2) gene, and the 3-beta hydroxysteroid dehy-
drogenase II (HSD3B2) gene. After adjustment for multiple
testing, 4 SNPs (rs9470080, rs9394309, rs7748266 and
rs1360780) showed significantly lower cortisolAUC per minor
allele. These SNPs are all located in the FKBP5 gene and in
strong LD with each other.
3.3. GWAS of cortisol and the replication study
Table 4 presents the results of the GWAS, the replication and
the meta-analysis. The most significant association was found
between rs8026512 on chromosome 15 with a lower cortiso-
lAUC per C allele (beta = 0.57, p-value 6.04  10(6)). The
second hit (rs11630255) was in LD with rs8026512 and showed
a similar association with cortisol (beta = 0.57, p-value
7.45  10(6)) so was not selected for replication. The third
hit with a p-value < 1  10(5) (rs2252459) was associated
with a higher cortisolAUC per C allele (beta 0.53, p-value
8.75  1(6)). It is located in intron 3 of the activated
leukocyte cell adhesion molecule (ALCAM) gene on chromo-
some 3 (3q13.1). There were no other hits with a p-value < 1  10(5). Within the first ten hits of the GWAS,
we found two SNPs (rs9470080 and rs9394309) that were also
identified in the candidate gene study above. These SNPs,
located in the FKBP5 gene region, were associated with a
lower cortisolAUC per risk allele (rs9470080: beta = 0.55, p-
value 1.26  10(5); rs9394309: beta = 0.56, p-value
1.58  10(5)). The first 50 hits of the GWAS, the Q-Q plot
and Manhattan plot are included in the SM (see (SM) Table 3
and Figs. 1 and 2). The GWAS stratified on gender (776 males
and 931 females) yielded less SNPs with p-values of
1  10(5) or smaller than the GWAS in the whole sample.
Two top SNPs of the GWAS in the whole sample were also
found among the top hits in the stratified analyses; males
rs9470080 p-value 9.95  10(5), females rs8026512 p-value
1.94  10(5). The results of the stratified analyses are
presented in Table 4a (males) and Table 4b (females) of
the supplementary material.
To replicate our main findings, top hit SNPs (rs8026512,
rs2252459, rs9470080 and rs9394309) were genotyped in the
Whitehall II study.Of the four SNPs, two (rs8026512 and
rs2252459) were associated with the cortisolAUC in the repli-
cation cohort; however, the effects were in the opposite
direction. Hence, none of the initial SNPs associated with
cortisol secretion in the GWAS sample were successfully
replicated.
The association of candidate genes and clinically relevant
depressive symptoms.
Table 5 presents the association between the 4 SNPs which
remained significant after adjustment for multiple testing in
the candidate gene analysis, and depressive symptoms. Since
these SNPs are in strong LD, our results were not corrected for
multiple testing. Carriers of minor alleles of rs9470080 were
at an increased risk of depressive symptoms (OR1.19, 95%CI
1.01; 1.40, p-value 0.037).
The distribution of gender, age, educational level, smoking,
DM type II, CHD and use of hypnotics did not differ between
carriers of rs9470080 and non-carriers. In contrast, carriers of
Table 2 Selected candidate genes expected to explain
variation in cortisol secretion.
Gene Symbola No. of SNPs
(Illumina550k)
Position
Corticosteroid biosynthesis
CYP21A2 35 6:32014061-32217398
CYP11B1 35 8:143850775-144058238
CYP17A1 35 10:104480278-104687280
HSD3B2 39 1:119659296-119867174
CYP11A1 48 15:72317156-72547134
MC2R 48 18:13774624-13975517
STAR 7 8:38019375-38227757
PRKAR1A 41 17:63923130-64159026
Central HPA-axis control & negative feedback
NR3C1 58 5:142537689-142863447
NR3C2 104 4:149120957-149677462
AVP 45 20:2911203-3113370
AVPR1A 44 12:61726483-61932857
CRH 24 8:67,251,173- 67,253,252
CRHR1 47 17:41117449-41368973
CRHR2 53 7:30559388-30788665
POMC 34 2:25137226-25345063
MC4R 48 18:56089544-56290981
POU1F1 42 3:87291473-87508427
PROP1 26 5:177251842-177455849
TBX19 49 1:166416902-166650288
LEPR 82 1:65558906-65975410
LEP 37 7:127568567-127784918
FKBP5 48 6:35549346-35864692
Cortisol inactivation and metabolism
HSD11B2 8 16:65922537-66128955
HSD11B1 58 1:207826173-208074918
DHRS9 32 2:169534209-169746650
SRD5A1 78 5:6586500-6822675
SRD5A2 20 2:31503160-31759544
AKR1D1 56 7:137327054-137553590
CYP3A4 20 7:99092540-99319744
H6PD 55 1:9117450-9353981
SERPINA6 73 14:93740338-93959441
ACE 26 17:58808166-59048711
33 genes 1456 SNPs
Abbeviations: SNP, single nucleotide polymorphism.
a Full gene names are given in supplementary material (SM)
Table 1.
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antipsychotics compared with non-carriers (SM Table 5).
4. Discussion
This study from two well-characterized European cohorts of
middle-aged or elderly adults used candidate gene and gen-
ome wide approaches to identify genes associated with
diurnal cortisol secretion and their association with depres-
sive symptoms. We found evidence for an association of
FKBP5 SNP rs9470080 with both saliva cortisol concentrations
and depressive symptoms.
FKBP5 is a co-chaperone of hsp90, which is part of a
receptor complex that regulates the sensitivity of the glu-cocorticoid receptor (GR). An increase in FKBP5 gene expres-
sion leads to an increased resistance of GR to cortisol, which
may result in hypercortisolism (Binder, 2009). GWAS and
linkage studies, one of which includes data from the Rotter-
dam Study, did not report SNPs within the FKBP5 gene as one
of the most significant associations (Bosker et al., 2010;
Muglia et al., 2010; Schol-Gelok et al., 2010). In previous
candidate gene studies, FKBP5 SNPs have been associated
with depression (Lekman et al., 2008; Zobel et al., 2010), the
recurrence of depressive episodes, the response to antide-
pressant treatment (Binder et al., 2004; Zou et al., 2010),
peritraumatic dissociation in children (Koenen et al., 2005),
bipolar disorder (Willour et al., 2009), and suicide behaviour
(Brent et al., 2010; Roy et al., 2010). FKBP5 gene expression
was associated with posttraumatic stress disorder (PTSD)
(Yehuda et al., 2009). Furthermore, carriers of FKBP5 SNPS
showed insufficient recovery of cortisol levels after psycho-
social stress (Ising et al., 2008). Also, interaction effects have
been found with FKBP5 SNPs and childhood abuse on PTSD
(Binder et al., 2008) and FKBP5 SNPs and resistant attach-
ment on cortisol reactivity in infants (Luijk et al., 2010). Most
studies examined the effect of FKBP5 SNPs under stressful
circumstances only. Such a paradigm may activate different
regulatory mechanisms than those regulating basal cortisol
secretions.
In the present study, carriers of genetic variants in the
FKBP5 gene had a lower cortisolAUC and an increased risk of
depressive symptoms compared with non-carriers. The latter
finding is in line with the observation that TT-carriers of the
FKBP5 rs1360780 variant are more likely to have recurrent
and treatment-refractory depression. However, depression is
typically associated with high cortisol levels. Several aspects,
other than a chance finding, must be considered when inter-
preting these findings. Firstly, the relation between depres-
sion and hypercortisolism is less consistent than frequently
stated. In a meta-analysis, Burke and colleagues showed that
the association between depression and cortisol levels at
baseline strongly depends on the time of day. In the morning,
depressed patients show lower cortisol levels than non-
depressed individuals. In the afternoon, cortisol levels are
higher among depressed patients compared to non-depressed
individuals. Also, Oldehinkel et al. (2001) found that hypo-
cortisolism, and not hypercortisolism, was related to chronic
depressive episodes. Furthermore, Penninx et al. (2007)
reported a U-shaped relation between depression and corti-
sol among elderly subjects. In this study, depressed elders
with the lowest cortisol levels also scored higher on frailty
indicators than depressed elders with cortisol levels in the
highest tertile. Furthermore, hypocortisolism has been asso-
ciated with depression in elderly females (Bremmer et al.,
2007). This may explain the association of FKBP5 SNPs with
lower cortisolAUC and depression in our study, since our study
of elderly was predominantly female. Second, depression in
community-dwelling elderly is typically more chronic as a
consequence of the ascertainment, but acute and clinical
depression is characterized by high levels of cortisol. Third,
we studied depressive symptoms and not a clinical diagnosis
of depression or subtypes of depression. However, the obser-
vation that carriers of FKBP5 rs9470080 were more likely to
report clinically relevant depressive symptoms and also more
likely to use antidepressants or antipsychotics further indi-
cates that depressive symptoms are a good marker of severe
Table 3 The association of candidate gene SNPs with cortisolAUC.
SNP Gene Chr. Variant MAF beta se p-value unadj. p-value adj. a
Most significant No. significant
Cortisolauc (nmol/L)
rs9470080 4 FKBP5 6 G > A 0.34 0.55 0.12 1.0e05 0.001
rs11152221 — MC4R 18 G > A 0.32 0.36 0.12 3.1e03 0.18
rs2284218 — CRHR2 7 A > G 0.36 0.34 0.12 5.6e03 0.35
rs2296236 — AVP 20 G > A 0.16 0.44 0.16 7.1e03 0.40
rs7735244 — SRD5A1 5 A > G 0.10 0.50 0.19 9.6e03 0.44
rs10519942 — NR3C2 4 G > A 0.07 0.59 0.23 0.009 0.48
rs6672903 — HSD3B2 1 A > G 0.44 0.30 0.12 0.012 0.59
Abbreviations: SNP, single nucleotide polymorphism; Chr., chromosome; MAF, minor allele frequency; se, standard error.
a Adjusted for multiple testing using Max(T) permutation (10.000).
Table 4 Main findings GWAS cortisolAUC and replication results.
SNP Gene Chr. Variant Rotterdam Study
(n = 1711)
Whitehall II Study
(n = 2836)
Meta-analysis
(n = 4547)
beta p-value beta p-value beta p-value
CortisolAUC (nmol/L)
rs8026512 — 15 T > C 0.57 6.04e06 0.13 0.037 0.01 0.830
rs2252459 ALCAM 3 T > C 0.53 8.75e06 0.13 0.039 0.01 0.803
rs9470080 FKBP5 6 G > A 0.55 1.26e05 0.025 0.702 0.14 0.017
rs9394309 FKBP5 6 A > G 0.56 1.58e05 0.006 0.927 0.12 0.037
Abbreviations: SNP, single nucleotide polymorphism; Chr., chromosome.
1058 F.P. Velders et al.psychiatric disorders. Also, we did not rule out persons with
depressive symptoms due to PTSD, fibromyalgia or chronic
fatigue, which have been associated with hypocortisolism
(Fries et al., 2005). Finally, the relation between FKBP5
variants and depression could not be explained by the cortisol
parameters in the present study as there was no association
between cortisolAUC and depressive symptoms. This can
reflect a lack of power, but could also indicate that another
mechanism than basal cortisol regulation underlies the
observed associations.
The GWAS approach identified two SNPs which are poten-
tially relevant for cortisol secretion. Our top hit (rs8026512)
was located on chromosome 15 in the Prader Willi syndrome
(PWS) deletion region. This syndrome is a neurobehavioural
disorder characterized by hypertonia, failure to thrive,Table 5 Results of the association of FKBP5 SNPs with depressiv
Chr. SNP Position Variant C
D
n
O
6 rs9470080 35754413 G ! A 1
6 rs9394309 35729759 A ! G 1
6 rs7748266 35700722 G ! A 1
6 rs1360780 35715549 G ! A 1
Abbreviations: CES-D, Centrum for Epidemiology Studies Depression 
nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
a Reference = CES-D depressive symptoms score < 16.hyperphagia, short stature, hypogonadism and developmen-
tal delay. de Lind van Wijngaarden et al. (2008) reported a
60% prevalence of central adrenal insufficiency in PWS
patients, which is characterized by insufficient cortisol.
The second hit (rs2252459) is located in intron 3 of the
activated leukocyte cell adhesion molecule (ALCAM) gene
on chromosome 3 (3q13.1). This cell adhesion molecule is
expressed by epithelial cells in several organs. Alterations in
the expression of ALCAM have been reported in several
human tumours (Ofori-Acquah and King, 2008). Although it
is not directly clear how ALCAM may influence cortisol secre-
tion, there may be a link between ALCAM and cortisol via the
immune system.
The replication of the association of four SNPs with corti-
solAUC from the GWAS in the Rotterdam Study (RS) was note symptoms (n = 2928).
ES-D
epressive symptoms score  16a
 = 375
LD with
rs9470080
R 95%CI p-value DR2 D0
.19 1.01;1.40 0.037 — —
.15 0.97;1.35 0.107 0.95 1
.16 0.95;1.43 0.151 0.46 1
.18 1.00;1.39 0.057 0.84 1
Scale; LD, linkage disequilibrium; Chr, chromosome; SNP, single
Genetics of cortisol secretion and depressive symptoms 1059successful in the Whitehall II study. The associations found in
the replication sample were not in the same direction and
had thus not been hypothesized based on the initial GWAS.
They were also not significant after Bonferroni correction.
Inconsistent findings may be the result of false-positive
findings in the GWAS, or falsely non-replicated true GWAS
findings in the replication sample (Ioannidis, 2007). Due to
the number of tests performed in a GWAS, the frequency of
false-positive findings is high. In this study with 1711 partici-
pants, we had sufficient power (0.80) to detect an R2 change of
0.0045 (Quanto 1.2.4 (Gauderman, 2003,2006)). We had 0.55
power to detect the effect sizes (beta 0.56) associated with
our strongest hits. Furthermore, phenotyping and genotyping
errors may account for false-positive findings in a GWAS.
However, in both studies cortisol data were obtained by saliva
sampling at home with several samples on one day, and cortisol
levels were assessed in the same laboratory. Albeit statistically
significant, the differences in cortisol levels were small.
Hence, the phenotype definition is unlikely to account for
the non-replication. The other differences between the two
studies are likely the results of the difference in inclusion
criteria of both studies. The WHII Study consists of civil ser-
vants from London which implies that the study population
has, on average, a high educational level and more men. This
high social economic status may account for differences in the
prevalence of disease, and the use of hypnotics. It has been
reported that cortisol levels increase with age (Van Cauter
et al., 1996; Seeman et al., 2001). Also, there is evidence to
suggest that cortisol levels are higher in older men than older
women (Seeman et al., 2001). Grant et al. (2007) reported
higher urinary free cortisol levels in depressed men than in
depressed women. These urinary free cortisol levels in
depressed males further increased with age and severity of
the illness. As the participants of the Rotterdam Study and the
Whitehall II Study were all older adults, it seems unlikely that
difference in age accounts for the non-replication. Gender
distribution in the two cohorts was different with a majority of
female participants in the Rotterdam Study and a majority of
males in the replication sample. However, the GWAS of corti-
solAUC stratified on gender did not yield associations with lower
p-values, which is likely due to insufficient power. The GWAS
and the replication study were not adjusted for other covari-
ates related to cortisol levels, since SNP associations are very
unlikely to be confounded by these variables. This is because
most confounding factors do not alter an individual’s genetic
make-up. Adjusting for covariates that affect cortisol secre-
tion may increase precision of our phenotype, but could also
blunt the measured gene-phenotype association (Koepsell and
Weiss, 2003).
Next to cortisolAUC, the single cortisol measurements and
the cortisol awakening response (CAR) are frequently used
phenotypes of cortisol secretion. In this study, we focused on
the cortisolAUC, because this daytime profile gives more
information about the HPA-axis activity than the single cor-
tisol measurements and reduces the risk of multiple testing
(Pruessner et al., 2003). The CAR was not used as outcome
measurement, because its exact function remains to be
determined and conflicting results, both an elevated CAR
as well as a blunted CAR, in relation to depression have been
found (Fries et al., 2009).
Next to false-positive findings, it could be that our GWAS
findings were falsely non-replicated in the WHII study. Thismay be due to phenotyping and genotyping errors or low
power. As discussed previously, the phenotyping in the two
samples was very comparable. Also, all SNPs were in HWE and
there was no miscoding of major versus minor alleles. To
improve power, replication studies with substantially larger
sample sizes are needed to reliably determine whether we
observed true associations or chance findings in the GWAS of
cortisolAUC.
At least two other studies have used a genome wide
approach to identify genes associated with cortisol secretion.
Ukkola et al. (2002) performed a genome wide linkage scan
on morning serum cortisol in black and white families, but did
not find evidence for linkage between any of the microsa-
tellite markers and cortisol. A subsequent family-based link-
age study identified a significant association between
morning serum cortisol and two markers on chromosome
11 and 14 in women (Kurina et al., 2005). Although saliva
cortisol levels and serum cortisol levels are highly correlated
(Kirschbaum and Hellhammer, 1994; Gozansky et al., 2005),
morning levels of cortisol tend to be highly variable due to
the steep morning rise and do not represent cortisolAUC well.
Therefore, the lack of power to identify complex gene
variants using the linkage approach, and the difference in
phenotype definition are likely to account for the lack of
congruence between these two studies and our study.
In conclusion, we found an association of FKBP5 SNPs with
a decrease in cortisolAUC in a population-based cohort. Car-
riers of FKBP5 minor alleles were also at increased risk of
clinically relevant depressive symptoms. Although this is
consistent evidence for the physiological and clinical rele-
vance of variants in this HPA-axis regulating gene in an
epidemiological study, future laboratory studies are needed
to establish the causal mechanism behind these associations.
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